Contraception Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Contraception - Pipeline Review, H1 2015” to its store. The report provides an overview of the Contraception’s therapeutic pipeline.

Contraception Therapeutic Pipeline Review H1 2015

Contraception Therapeutic Pipeline Review H1 2015

Past News Releases

RSS

The report “Contraception - Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Contraception. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/contraception-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Contraception and special features on late-stage and discontinued projects. Companies discussed in this Contraception - Pipeline Review, H1 2015 report include Actavis plc, Agile Therapeutics, Inc., ANI Pharmaceuticals, Inc., Antares Pharma, Inc., Evofem, Inc., Hydra Biosciences, Inc., Intas Pharmaceuticals Ltd., Ligand Pharmaceuticals, Inc., Merck & Co., Inc., Orbis Biosciences, Inc., Pantarhei Bioscience BV and Teva Pharmaceutical Industries Limited.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are (ethinyl estradiol + levonorgestrel), (ethinylestradiol + levonorgestrel), (nestorone + estradiol), (prasterone + estradiol + progesterone), AG-200 ER, AG-200 SP, Amphora, esterol, etonogestrel, EVE-106, levonorgestrel, LJ-102, MK-8342B, Monoclonal Antibody Conjugates for Contraception, norethindrone, S-003296, S-0101255, Small Molecule 1 for Fertility Control, Small Molecule to Modulate Progesterone Receptor for Fertility Control and Small Molecules to Block CatSper1 Ion Channel for Contraception.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=394574 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report include: Jan 13, 2015: Evofem Announces Pre-NDA Meeting With FDA for Amphora. Dec 01, 2014: Agile Therapeutics Announces Publication of Data on Low-Dose Investigational Contraceptive Patch. Sep 29, 2014: Agile Announces Dosing of First Patients in Twirla Phase 3 SECURE Study. Sep 16, 2014: Agile Initiates Phase 3 SECURE Study for Twirla. Jul 17, 2014: Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion. Jul 04, 2014: Teva Receives CHMP Positive Opinion for Seasonique Extended-Regimen Contraceptive for Marketing Authorization in Several European Countries. Jun 26, 2014: Evofem Announces the Completion of the Largest Phase III Contraceptive Clinical Trial to Date. Jun 20, 2014: Agile Therapeutics Announces Issuance of New Patent for Its Skinfusion Transdermal Delivery Device. Jul 24, 2013: Health Decisions Completes Enrollment of Evofem's 3,400-subject Global Trial of Amphora® Non-hormonal Contraceptive Gel. Jul 23, 2013: Enrollment Completed for Evofem's 3,200-subject Global Trial of Amphora Non-hormonal Contraceptive Gel.

List of Tables
Number of Products under Development for Contraception, H1 2015 10
Number of Products under Development for Contraception - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Comparative Analysis by Unknown Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Contraception - Pipeline by Actavis plc, H1 2015 22
Contraception - Pipeline by Agile Therapeutics, Inc., H1 2015 23
Contraception - Pipeline by ANI Pharmaceuticals, Inc., H1 2015 24
Contraception - Pipeline by Antares Pharma, Inc., H1 2015 25
Contraception - Pipeline by Evofem, Inc., H1 2015 26
Contraception - Pipeline by Hydra Biosciences, Inc., H1 2015 27
Contraception - Pipeline by Intas Pharmaceuticals Ltd., H1 2015 28
Contraception - Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 29

List of Figures
Number of Products under Development for Contraception, H1 2015 10
Number of Products under Development for Contraception - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Products, H1 2015 17
Assessment by Monotherapy Products, H1 2015 34
Assessment by Combination Products, H1 2015 35
Number of Products by Top 10 Targets, H1 2015 36
Number of Products by Stage and Top 10 Targets, H1 2015 37
Number of Products by Top 10 Mechanism of Actions, H1 2015 38
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 39
Number of Products by Top 10 Routes of Administration, H1 2015 40
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 41
Number of Products by Top 10 Molecule Types, H1 2015 42
Number of Products by Stage and Top 10 Molecule Types, H1 2015 43

Explore more reports on Women's Health therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/womens-health-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@RnRMR
since: 06/2012
Follow >
RnR Market Research
Like >
Follow us on